Jefferies Maintains Buy Rating on Ariad Pharma
According to Jefferies, Ariad Pharma (NASDAQ: ARIA) Buy rating is maintained.
Jefferies said that in ASH oral presentation for ponatinib Ph2 study (PACE), interim numerical efficacy data is similar to that in abstract (but in a larger # of pts). “At median 5.6-month FU, overall CP-CML MCyR was ~47% (vs. 46% previously); non-T315i/T315i mutation MCyR was 41%/65%, with improved T315iM response vs. previously. Additional details at ARIA Investor Breakfast on Dec. 12.”
Ariad Pharma closed on Friday at $13.60.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.